Products Categories
Basic Information
| CAS No.: | 51-64-9 |
|---|---|
| Name: | D-AMPHETAMINE HYDROCHLORIDE |
| Article Data: | 169 |
| Molecular Structure: | |
|
|
|
| Formula: | C9H13 N |
| Molecular Weight: | 135.209 |
| Synonyms: | Benzeneethanamine,a-methyl-, (S)-;Phenethylamine, a-methyl-, (+)- (8CI);(+)-(S)-Amphetamine;(+)-Phenaminum;(+)-a-Methylphenethylamine;(2S)-(+)-Amphetamine;(S)-(+)-Amphetamine;(S)-(+)-b-Phenylisopropylamine;(S)-1-Methyl-2-phenylethylamine;(S)-1-Phenyl-2-aminopropane;(S)-1-Phenyl-2-propanamine;(S)-1-Phenyl-2-propylamine;(S)-Amphetamine;(S)-a-Methylphenethylamine;D-(+)-Amphetamine;D-Amphetamine;Dexadrine;Dexamfetamine;Dexamphetamine;Dextroamphetamine;Metamina;NSC 73713;d-(S)-Amphetamine;d-Amphetamine;(+)-Amphetamine; |
| EINECS: | 200-112-1 |
| Density: | 0.946 g/cm3 |
| Melting Point: | 25°C |
| Boiling Point: | 201.5 °C at 760 mmHg |
| Flash Point: | 87.4 °C |
| Solubility: | Slightly soluble in water. |
| Appearance: | Colorless, oily liquid. |
| Hazard Symbols: | F,T |
| Risk Codes: | 11-23/24/25-39/23/24/25 |
| Safety: | Poison by ingestion, subcutaneous, intravenous, and intraperitoneal routes. Experimental reproductive effects. Chronic exposure causes central nervous system damage and blood-pressure effects. When heated to decomposition it emits toxic NOx. See other amphetamine entries. |
| PSA: | 26.02000 |
| LogP: | 3.07860 |
Related products
- 81281-59-67-Benzylideneaminotheophylline
- 82993-81-5D-threo-Ritalinic acid hydrochloride
- 73441-42-6METHYL-5-CHLORO-2,2-DIMETHYLVALERATE
- 68439-39-4Poly(oxy-1,2-ethanediyl), alpha-(2-ethylhexyl)-omega-hydroxy-,
- 852475-26-4MC1568
- 958254-66-51H-Imidazo[4,5-b]pyridine-2-carboxaldehyde, 1-methyl-, hydrochloride
- 99170-93-1N-Methyl-2-oxazolamine
- 717878-06-31-(4-fluorophenyl)-4-nitro-1H-imidazole
- 914458-26-7[5-(2-fluorophenyl)-1-pentyl-1H-pyrrol-3-yl]-1-naphthalenyl-Methanone
- 548773-13-32-amino-4,6-dimethylpyrimidine-5-carboxylic acid
Downstream Products
This product is a nationally controlled contraband, and the Lookchem platform doesn't provide relevant sales information.
Chemistry
The molecular formula of d-Amphetamine(51-64-9) is C9H13N and its molecular weight is 135.20.
Synonyms:(-)-alpha-Phenylpropylamine;(S)-(+)-beta-Phenylisopropylamine;alpha-Methylphenethylamine, d-form;alpha-methylphenethylamine,d-form;amphetamine(d);Amphetamine, (d);Benzeneethanamine, alpha-methyl-, (S)-;component of Amodex
Molecular Structure:
History
1、d-amphetamine was first synthesized under the chemical name "phenylisopropylamine" in Berlin, 1887 by the Romanian chemist Lazar Edeleanu. It was not widely marketed until 1932.
Three years later, in 1935, the medical community became aware of the stimulant properties of amphetamine.
2、In 1937 Smith, Kline, and French introduced tablets under the tradename Dexedrine.
3、It quickly became apparent that dextroamphetamine and other amphetamines had a high potential for misuse, although they were not heavily controlled until 1970.
4、Internationally, it has been available under the names AmfeDyn (Italy), Curban (US), Obetrol (Switzerland), Simpamina (Italy), Dexedrine (US), Dextropa (Portugal), and Stild (Spain).
Three years later, in 1935, the medical community became aware of the stimulant properties of amphetamine.
2、In 1937 Smith, Kline, and French introduced tablets under the tradename Dexedrine.
3、It quickly became apparent that dextroamphetamine and other amphetamines had a high potential for misuse, although they were not heavily controlled until 1970.
4、Internationally, it has been available under the names AmfeDyn (Italy), Curban (US), Obetrol (Switzerland), Simpamina (Italy), Dexedrine (US), Dextropa (Portugal), and Stild (Spain).
Uses
d-Amphetamine(51-64-9) is used as CNS stimulant; anorexic. More active isomer of Amphetamine. Induces release of catecholamines and serotonin by displacing the monoamines from their vesicular storage sites; blocks catecholamine reuptake. Controlled substance (stimulant).
Toxicity Data With Reference
| 1. | scu-rat TDLo:25 mg/kg (female 5-9 D post):REP | DABBBA Dissertation Abstracts International, B: The Sciences and Engineering. 31 (1971),6304. | ||
| 2. | orl-man TDLo:42 mg/kg/25 W-I | BIPCBF Biological Psychiatry. 20 (1985),1332. | ||
| 3. | orl-cld TDLo:3600 µg/kg/10 D-I | AJPSAO American Journal of Psychiatry. 143 (1985),1176. | ||
| 4. | orl-rat LD50:38 mg/kg | TXAPA9 Toxicology and Applied Pharmacology. 18 (1971),185. | ||
| 5. | ipr-rat LDLo:20 mg/kg | AEPPAE Naunyn-Schmiedebergs Archiv fuer Experimentelle Pathologie und Pharmakologie. 195 (1940),647. | ||
| 6. | scu-rat LD50:200 mg/kg | 27ZIAQ Drug Dosages in Laboratory Animals-A Handbook C.D. Barnes andL.G. Eltherington,Berkeley, CA.: Univ. of California Press,1973,84. | ||
| 7. | orl-mus LD50:40 mg/kg | TXAPA9 Toxicology and Applied Pharmacology. 41 (1977),329. | ||
| 8. | ipr-mus LD50:4400 µg/kg | AIPTAK Archives Internationales de Pharmacodynamie et de Therapie. 161 (1966),206. | ||
| 9. | scu-mus LD50:20 mg/kg | AIPTAK Archives Internationales de Pharmacodynamie et de Therapie. 146 (1963),392. | ||
|
Consensus Reports
d-Amphetamine(51-64-9) is reported in EPA TSCA Inventory.
Safety Profile
RIDADR： 3249
HazardClass： 6.1(a)
PackingGroup： II
Poison by ingestion, subcutaneous, intravenous, and intraperitoneal routes. Experimental reproductive effects. Chronic exposure causes central nervous system damage and blood-pressure effects. When heated to decomposition it emits toxic NOx. See other amphetamine entries.
Specification
Contraindications
Do not use in patients with a history of drug abuse. Do not use during or within 14 days following the administration of MAO inhibitors; hypertensive crises may result. Advanced arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension, hyperthyroidism, known hypersensitivity or idiosyncrasy to the sympathomimetic amines, glaucoma and agitated states. Amphetamines should not be used to combat fatigue or to replace rest.
Do not use in patients with a history of drug abuse. Do not use during or within 14 days following the administration of MAO inhibitors; hypertensive crises may result. Advanced arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension, hyperthyroidism, known hypersensitivity or idiosyncrasy to the sympathomimetic amines, glaucoma and agitated states. Amphetamines should not be used to combat fatigue or to replace rest.